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AF

:   atrial fibrillation

HR

:   hazard ratio

PMED

:   peripheral microvascular endothelial dysfunction

RH‐PAT

:   reactive hyperemia peripheral arterial tonometry

Clinical PerspectiveWhat Is New?Peripheral microvascular endothelial dysfunction, defined as reactive hyperemia peripheral arterial tonometry index ≤2.0 was associated with a \>3‐fold increased risk of ischemic stroke.Assessment of peripheral microvascular endothelial dysfunction added prognostic value to CHA~2~DS~2~‐VASc score or revised Framingham Stroke Risk Score (aged ≥55 years) in predicting ischemic stroke.What Are the Clinical Implications?Findings underscore the concept of the systemic nature of endothelial dysfunction, which could act as a potential marker to predict future risk of ischemic stroke.

Introduction {#jah35062-sec-0008}
============

Measurement of peripheral vasomotor response as a measure for endothelial dysfunction has been linked to adverse cardiovascular outcomes.[1](#jah35062-bib-0001){ref-type="ref"} Reactive hyperemia peripheral arterial tonometry (RH‐PAT) is a non‐invasive method to measure the vasomotor response using fingertip device. RH‐PAT index correlated well with coronary microvascular endothelial function and can be used to non‐invasively assess peripheral microvascular endothelial dysfunction (PMED), which is associated with increased risk of late cardiovascular adverse events in individuals with minimal cardiovascular risk factors. Thus, PMED could be viewed as an early feature of vascular disease.[2](#jah35062-bib-0002){ref-type="ref"}, [3](#jah35062-bib-0003){ref-type="ref"}, [4](#jah35062-bib-0004){ref-type="ref"}

Endothelial cells play a key role in cerebral circulation: (1) endothelial cells are the site of blood brain barrier, thus controlling the movement of ions, molecules, and cells, (2) endothelial cells affect resting cerebral blood flow as well as vasomotor responses to shear stress, neurotransmitters, and metabolic factors, and (3) endothelial cells affect the function of neurons, microglia, and oligodendrocytes.[5](#jah35062-bib-0005){ref-type="ref"} Therefore, endothelial dysfunction may predispose brain tissue to be at risk for ischemic injury during decrease in perfusion pressure. However, there is a lack of evidence to show the association between PMED and ischemic stroke.

Atrial fibrillation (AF) is a well‐known cause of left atrial thrombus formation, leading to massive cardioembolic stroke.[6](#jah35062-bib-0006){ref-type="ref"} However, only ≈50% to 60% of ischemic strokes in patients with AF were reported to be cardioembolic in etiology, whereas one third of ischemic strokes might be lacunar infarcts caused by small vessel occlusion.[7](#jah35062-bib-0007){ref-type="ref"}, [8](#jah35062-bib-0008){ref-type="ref"} Increased levels of circulating von Willebrand factor and soluble E‐selectin, both of which are correlated with endothelial dysfunction, were associated with an increased risk of ischemic stroke in real‐world AF patients,[9](#jah35062-bib-0009){ref-type="ref"} suggesting the link between endothelial dysfunction and ischemic stroke. CHA~2~DS~2~‐VASc score (congestive heart failure, hypertension, aged ≥75 years, diabetes mellitus, stroke or transient ischemic attack, peripheral artery disease, aged 65--74 years, sex category) was created to predict the risk of ischemic stroke in patients with non‐valvular AF, and is widely used to guide antithrombotic therapy in this patient group.[10](#jah35062-bib-0010){ref-type="ref"}, [11](#jah35062-bib-0011){ref-type="ref"}, [12](#jah35062-bib-0012){ref-type="ref"} In contrast, recently published clinical studies have demonstrated that use of the CHA~2~DS~2~‐VASc score in predicting ischemic stroke has extended to patients without AF for which it was not initially proposed.[13](#jah35062-bib-0013){ref-type="ref"}, [14](#jah35062-bib-0014){ref-type="ref"}, [15](#jah35062-bib-0015){ref-type="ref"}, [16](#jah35062-bib-0016){ref-type="ref"}

We hypothesized that PMED could predict the future risk of ischemic stroke. This study aimed to investigate the association between PMED and the incidence of ischemic stroke. Also, we sought to assess the incremental prognostic value provided by PMED in predicting ischemic stroke when combined with the CHA~2~DS~2~‐VASc score or revised Framingham Stroke Risk Score.

Methods {#jah35062-sec-0009}
=======

The data that supported the findings of this study are available from the corresponding author upon reasonable request.

Study Population {#jah35062-sec-0010}
----------------

In this observational cohort study, we enrolled 637 patients who visited the Mayo Clinic between January 2006 and February 2014 and underwent endothelial function testing using the EndoPAT 2000 device (Itamar Medical Inc., Caesarea, Israel) for the assessment of cardiovascular risk and/or chest pain. Endothelial function was evaluated at the clinical discretion of the evaluating physician. This study was conducted in accordance with the guidelines of the Declaration of Helsinki, and the Mayo Clinic Institutional Review Board approved the study protocol. All patients provided written informed consent for participation in the current study.

Assessment of Microvascular Endothelial Function {#jah35062-sec-0011}
------------------------------------------------

The peripheral microvascular endothelial function was evaluated by RH‐PAT, as previously described.[3](#jah35062-bib-0003){ref-type="ref"}, [17](#jah35062-bib-0017){ref-type="ref"}, [18](#jah35062-bib-0018){ref-type="ref"}, [19](#jah35062-bib-0019){ref-type="ref"} Briefly, the study protocol included a 5‐minute baseline measurement, followed by 5‐minute inflation of a blood pressure cuff around the test arm with a pressure of 60 mm Hg above baseline systolic blood pressure up to 200 mm Hg, followed by a 6‐minute PAT measurement after deflation of the cuff. Blood pressure cuff occlusion was not applied to the control arm (contralateral arm). RH‐PAT ratio was determined as the average pulse wave amplitude for a 1‐minute‐period beginning 1 minute after pressure cuff deflation (test arm=A; control arm=C) divided by the average pulse wave amplitude during a 3.5‐minute baseline period (test arm=B; control arm=D). The RH‐PAT index was calculated automatically through a computer algorithm by normalizing baseline signal and indexing the RH‐PAT ratio on the test arm to that of the control arm: RH‐PAT index=(A/B)/(C/D) × baseline correction. All vasoactive medications, including calcium channel blockers, β‐blockers, and long‐acting nitrates, were discontinued for at least 24 hours before endothelial function testing. A calculated RH‐PAT index ≤2.0 was used as a cut‐off value for the diagnosis of peripheral microvascular endothelial dysfunction (PMED) in this study.[18](#jah35062-bib-0018){ref-type="ref"}, [20](#jah35062-bib-0020){ref-type="ref"}, [21](#jah35062-bib-0021){ref-type="ref"}, [22](#jah35062-bib-0022){ref-type="ref"}

Clinical Assessment {#jah35062-sec-0012}
-------------------

Clinical history, laboratory data, and current medications were collected from a detailed chart review by an investigator masked to RH‐PAT data. Data were collected on the following parameters: (1) sex, age, smoking status, and atrial fibrillation, (2) dyslipidemia, defined by a documented history of hyperlipidemia, treatment with lipid‐lowering therapy, a low‐density lipoprotein cholesterol level above the target (\<130 mg/dL for low risk patients, \<100 mg/dL for moderate‐high risk patients, \<70 mg/dL for high risk, and \<55 mg/dL for extremely high risk patients based on 10‐year atherosclerotic cardiovascular disease risk),[23](#jah35062-bib-0023){ref-type="ref"} high‐density lipoprotein cholesterol \<40 mg/dL in men or \<50 mg/dL in women, or triglycerides \>150 mg/dL, (3) type 2 diabetes mellitus, defined as a documented history of or treatment for type 2 diabetes mellitus, (4) hypertension, defined as a documented history of or treatment for hypertension, (5) coronary artery disease, defined as a documented history of myocardial infarction, revascularization, or \>50% luminal stenosis in any coronary artery diagnosed using coronary angiography or computed tomography coronary angiography, (6) peripheral vascular disease, including intermittent claudication, previous surgery or percutaneous intervention on the abdominal aorta or the lower extremity vessels, abdominal or thoracic surgery, arterial and venous thrombosis, and (7) a diagnosis of an ischemic stroke before and after the first RH‐PAT test. Ischemic stroke events were identified in accordance with the American Heart Association/American Stroke Association definition.[24](#jah35062-bib-0024){ref-type="ref"} All ischemic strokes were classified into cardioembolic, lacunar, and large artery disease, using modified TOAST (Trial of Org 10172 in Acute Stroke Treatment) criteria.[8](#jah35062-bib-0008){ref-type="ref"} All diagnoses of ischemic stroke were made by experienced neurologists at Mayo Clinic.

Calculation of CHA~2~DS~2~‐VASc Score and Revised Framingham Stroke Risk Score {#jah35062-sec-0013}
------------------------------------------------------------------------------

Based on CHA~2~DS~2~‐VSASc score, patients were given 1 point for congestive heart failure, hypertension, aged 65 to 74 years, diabetes mellitus, vascular disease, and female sex, and 2 points for aged ≥75 years and previous thromboembolism.[10](#jah35062-bib-0010){ref-type="ref"} Revised Framingham Stroke Risk Score was calculated using the published equations in patients ≥55 years.[25](#jah35062-bib-0025){ref-type="ref"}

Statistical Analysis {#jah35062-sec-0014}
--------------------

Continuous variables distributed normally were expressed as the mean±SD, and those with a skewed distribution were expressed as the median with interquartile range. Categorical variables were expressed as frequency (percentage). Enrolled patients were divided into 2 groups; those with PMED (RH‐PAT index ≤2.0) and those without PMED (RH‐PAT index \>2.0). For between‐groups comparisons, unpaired t test was used for normally distributed continuous variables, Mann--Whitney *U* test for non‐normally distributed variables, and χ^2^ test (and Fisher exact test) for categorical variables. Kaplan‐Meier methods were used to estimate ischemic stroke‐free survival rates. The difference between groups was analyzed using the log‐rank test. Univariate logistic regression analyses were performed to estimate the effects of PMED on the risk of ischemic stroke, with additional stratification by age, sex, and the presence of cardiovascular risk factors and atrial fibrillation. *P* value for interaction was calculated to assess if the effects of PMED on the risk of ischemic stroke differ between the subgroups. Additionally, univariate and multivariate Cox proportional hazard ratio (HR) analyses were performed to estimate the risk for ischemic stroke. In multivariable analyses, 4 covariate sets were investigated: (1) RH‐PAT index ≤2.0, sex, smoking history, atrial fibrillation, (2) RH‐PAT index ≤2.0, age, diabetes mellitus, hypertension, and dyslipidemia, (3) RH‐PAT index ≤2.0 and CHA~2~DS~2~‐VASc score, and (4) RH‐PAT index ≤2.0 and revised Framingham Stroke Risk Score. These covariate sets were chosen for clinical relevance. Finally, we evaluated the discriminatory power of the RH‐PAT index for identifying ischemic stroke when adding RH‐PAT index to CHA~2~DS~2~‐VASc score or revised Framingham Stroke Risk Score by calculating net reclassification improvement and integrated discrimination improvement. For all tests, a *P*\<0.05 was considered statistically significant. All statistical analyses were performed using JMP Pro software (SAS Institute, Inc., Cary, NC, USA) and R version 3.2.3 (R Foundation for Statistical Computing, Vienna, Austria).

Results {#jah35062-sec-0015}
=======

Baseline Characteristics {#jah35062-sec-0016}
------------------------

The baseline characteristics of the study population are summarized in Table [1](#jah35062-tbl-0001){ref-type="table"}. Of 637 patients, 280 patients (44.0%) had PMED, and 357 patients (56.0%) had normal peripheral microvascular endothelial function at baseline. Patients with PMED were more likely to have cardiovascular risk factors such as diabetes mellitus and dyslipidemia. Coronary artery disease was more prevalent in patients with PMED compared with those with normal peripheral microvascular endothelial function. Atrial fibrillation was detected in 15 patients (5.4%) with PMED and 15 patients (4.2%) with normal peripheral microvascular endothelial function (*P*=0.49). The frequency of a previous history of ischemic stroke was similar between patients with normal and abnormal peripheral microvascular endothelial function (n=20 \[5.6%\] versus n=14 \[5.0%\], respectively; *P*=0.74). CHA~2~DS~2~‐VASc score at baseline was not different between groups (*P*=0.94).

###### 

Baseline Characteristics of Patients With Normal vs Abnormal Peripheral Microvascular Endothelial Function

+-------------------------+-------------------+-------------------+-------------------+
| Characteristics         | Total (N=637)     | RH‐PAT Index      |                   |
+=========================+===================+===================+===================+
| Age, y                  | 52.0±13.6         | 51.8±13.5         | 52.1±13.7         |
+-------------------------+-------------------+-------------------+-------------------+
| Sex, n (%)              |                   |                   |                   |
+-------------------------+-------------------+-------------------+-------------------+
| Women                   | 389 (61.1)        | 155 (55.4)        | 234 (65.5)        |
+-------------------------+-------------------+-------------------+-------------------+
| Men                     | 248 (38.9)        | 125 (44.6)        | 123 (34.5)        |
+-------------------------+-------------------+-------------------+-------------------+
| Race, n (%)             |                   |                   |                   |
+-------------------------+-------------------+-------------------+-------------------+
| Whites                  | 578 (90.7)        | 258 (92.1)        | 320 (89.6)        |
+-------------------------+-------------------+-------------------+-------------------+
| Non‐Whites              | 59 (9.3)          | 22 (7.9)          | 37 (10.4)         |
+-------------------------+-------------------+-------------------+-------------------+
| Comorbidities, n (%)    |                   |                   |                   |
+-------------------------+-------------------+-------------------+-------------------+
| Hypertension            | 283 (44.4)        | 127 (45.4)        | 156 (43.7)        |
+-------------------------+-------------------+-------------------+-------------------+
| Diabetes mellitus       | 56 (8.8)          | 36 (12.9)         | 20 (5.6)          |
+-------------------------+-------------------+-------------------+-------------------+
| Dyslipidemia            | 450 (70.6)        | 213 (76.1)        | 237 (66.4)        |
+-------------------------+-------------------+-------------------+-------------------+
| Chronic kidney disease  | 83 (14.6)         | 41 (16.2)         | 42 (13.3)         |
+-------------------------+-------------------+-------------------+-------------------+
| Coronary artery disease | 144 (22.6)        | 76 (27.2)         | 68 (19.1)         |
+-------------------------+-------------------+-------------------+-------------------+
| Atrial fibrillation     | 30 (4.7)          | 15 (5.4)          | 15 (4.2)          |
+-------------------------+-------------------+-------------------+-------------------+
| Previous stroke         | 34 (5.3)          | 14 (5.0)          | 20 (5.6)          |
+-------------------------+-------------------+-------------------+-------------------+
| Smoking history, n (%)  | 234 (3.7)         | 107 (38.2)        | 127 (35.6)        |
+-------------------------+-------------------+-------------------+-------------------+
| Laboratory data         |                   |                   |                   |
+-------------------------+-------------------+-------------------+-------------------+
| LDL‐C, mg/dL            | 103 (80--127)     | 101 (78--125)     | 103 (83--129)     |
+-------------------------+-------------------+-------------------+-------------------+
| HDL‐C, mg/dL            | 54 (44--66)       | 50 (41--62)       | 58 (46--70)       |
+-------------------------+-------------------+-------------------+-------------------+
| Triglyceride, mg/dL     | 109 (77--158)     | 121 (80--183)     | 102 (74--147)     |
+-------------------------+-------------------+-------------------+-------------------+
| FPG, mg/dL              | 96 (90--104)      | 97 (92--105)      | 95 (89--102)      |
+-------------------------+-------------------+-------------------+-------------------+
| HbA1c, %                | 5.5 (5.2--5.9)    | 5.6 (5.2--6.0)    | 5.4 (5.2--5.9)    |
+-------------------------+-------------------+-------------------+-------------------+
| Creatinine, mg/dL       | 0.93±0.22         | 0.94±0.25         | 0.92±0.20         |
+-------------------------+-------------------+-------------------+-------------------+
| Systolic BP, mm Hg      | 122.1±16.7        | 121.5±16.6        | 122.6±16.8        |
+-------------------------+-------------------+-------------------+-------------------+
| Diastolic BP, mm Hg     | 79.4±11.0         | 73.8±9.9          | 75.8±11.8         |
+-------------------------+-------------------+-------------------+-------------------+
| RH‐PAT index            | 2.09 (1.74--2.53) | 1.70 (1.48--1.84) | 2.48 (2.22--2.79) |
+-------------------------+-------------------+-------------------+-------------------+
| Medications, n (%)      |                   |                   |                   |
+-------------------------+-------------------+-------------------+-------------------+
| Anti‐platelet           | 337 (52.9)        | 158 (56.4)        | 179 (50.1)        |
+-------------------------+-------------------+-------------------+-------------------+
| Statins                 | 269 (42.3)        | 130 (46.4)        | 139 (39.0)        |
+-------------------------+-------------------+-------------------+-------------------+
| Anti‐hypertensive       | 329 (51.7)        | 155 (55.4)        | 174 (48.7)        |
+-------------------------+-------------------+-------------------+-------------------+
| Anti‐diabetic           | 46 (7.3)          | 31 (11.2)         | 15 (4.2)          |
+-------------------------+-------------------+-------------------+-------------------+
| CHA~2~DS~2~‐VASc score  | 1 (1--2)          | 1 (1--2)          | 1 (1--2)          |
+-------------------------+-------------------+-------------------+-------------------+
| Revised FSRS (≥55 y)    | 2.2 (1.2--4.5)    | 2.7 (1.2--4.5)    | 1.9 (1.2--4.3)    |
|                         |                   |                   |                   |
|                         | n=287             | n=124             | n=163             |
+-------------------------+-------------------+-------------------+-------------------+

BP indicates blood pressure; FPG, fasting plasma glucose; FSRS, Framingham Stroke Risk Score; HbA1c, hemoglobin A1c; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; and RH‐PAT, reactive hyperemia peripheral arterial tonometry.

Impact of PMED on the Incidence of Ischemic Stroke {#jah35062-sec-0017}
--------------------------------------------------

During the median (interquartile range) follow‐up of 5.3 (0.4--13.6) years, 12 patients with PMED (4.3%) developed ischemic stroke, compared with 4 patients with normal peripheral microvascular endothelial function (1.1%). Among 12 ischemic stroke patients with PMED, 3 patients had AF and 2 of them were diagnosed as cardioembolic stroke. There were no AF‐related strokes in patients without PMED. Stroke‐free survival was significantly lower in patients with PMED compared with those without PMED (log‐rank *P*=0.03) (Figure [1](#jah35062-fig-0001){ref-type="fig"}). The association between PMED and risk of ischemic stroke during follow‐up is shown in Table [2](#jah35062-tbl-0002){ref-type="table"}. PMED was significantly associated with incident ischemic stroke in all individuals, patients aged ≥60 years, patients with dyslipidemia, and patients without diabetes mellitus (*P*=0.02, 0.02, 0.02, and 0.03, respectively). Odds ratio could not be calculated in men, patients without dyslipidemia, and patients with atrial fibrillation, because all patients in each group who developed ischemic stroke during follow‐up had PMED. We did not find significant interaction between these subgroups. Next, we performed univariate Cox proportional HR analyses to estimate the risk of ischemic stroke. PMED, age, atrial fibrillation, diabetes mellitus, hypertension, CHA~2~DS~2~‐VASc score, and Revised Framingham Stroke Risk Score were all associated with an increased risk of ischemic stroke during follow‐up (*P*=0.03, \<0.0001, 0.03, 0.04, 0.02, \<0.0001, and 0.002, respectively) (Table [3](#jah35062-tbl-0003){ref-type="table"}). PMED was an independent predictor of ischemic stroke during follow‐up after adjustment for other cardiovascular risk factors (multivariate model 1 and 2) or stroke risk score (multivariate model 3 and 4) (multivariate 1: adjusted HR, 3.70; 95% CI, 1.18--11.59, *P*=0.02; multivariate 2: adjusted HR, 3.36; 95% CI, 1.05--10.78, *P*=0.04; multivariate 3: adjusted HR, 3.45; 95% CI, 1.11--10.72, *P*=0.03; multivariate 4: adjusted HR 5.70; 95% CI, 1.40--23.29, *P*=0.02) (Table [4](#jah35062-tbl-0004){ref-type="table"}). PMED was a robust predictor of ischemic stroke even after adjustment for other components of the CHA~2~DS~2~‐VASc score individually, including congestive heart failure, myocardial infarction, and peripheral vascular diseases (adjusted HR 3.36, 95% CI, 1.05--10.78, *P*=0.04).

![Comparison of ischemic stroke‐free survival between patients with normal vs abnormal peripheral microvascular endothelial function.\
Out of 287 patients with reactive hyperemia peripheral arterial tonometry index ≤2.0, 12 patients (4.3%) developed ischemic stroke during follow‐up, whereas 4 out of 280 (1.1%) ischemic stroke was detected in patients with reactive hyperemia peripheral arterial tonometry index \>2.0. Patients with reactive hyperemia peripheral arterial tonometry index ≤2.0 had a lower ischemic stroke‐free survival compared with those with normal peripheral microvascular endothelial function at baseline (log‐rank *P*=0.03). RH‐PAT indicates reactive hyperemia peripheral arterial tonometry.](JAH3-9-e015703-g001){#jah35062-fig-0001}

###### 

Association Between RH‐PAT Index ≤2.0 and Risk of Incident Ischemic Stroke

  Stratified by         No. of Patients With RH‐PAT Index ≤2.0/All Patients (%)   No. of Patients With Incident Ischemic Stroke/All Patients (%)   Odds Ratio   95% CI          *P* Value   *P* for Interaction
  --------------------- --------------------------------------------------------- ---------------------------------------------------------------- ------------ --------------- ----------- ---------------------
  All individuals       280/637 (44.0)                                            16/637 (2.5)                                                     3.91         1.26 to 12.39   0.02        
  Sex                                                                                                                                                                                       
  Men                   125/248 (50.4)                                            6/248 (2.4)                                                      \*           \*              0.99        0.07
  Women                 155/389 (39.9)                                            10/389 (2.6)                                                     2.32         0.64 to 8.34    0.20        
  Age                                                                                                                                                                                       
  \<60 y                147/318 (46.2)                                            3/318 (0.9)                                                      2.34         0.21 to 26.12   0.48        0.60
  ≥60 y                 133/319 (41.7)                                            13/319 (4.1)                                                     4.96         1.34 to 18.38   0.02        
  Dyslipidemia                                                                                                                                                                              
  (−)                   67/187 (35.8)                                             1/187 (0.5)                                                      \*           \*              0.99        0.12
  (+)                   213/450 (47.3)                                            15/450 (3.3)                                                     4.66         1.30 to 16.73   0.02        
  Diabetes mellitus                                                                                                                                                                         
  (−)                   244/581 (42.0)                                            12/581 (2.1)                                                     4.26         1.14 to 15.92   0.03        0.53
  (+)                   36/56 (64.3)                                              4/56 (7.1)                                                       1.73         0.17 to 17.80   0.65        
  CAD                                                                                                                                                                                       
  (−)                   203/492 (41.3)                                            9/492 (1.8)                                                      2.90         0.72 to 11.75   0.14        0.59
  (+)                   76/144 (52.8)                                             7/144 (4.9)                                                      5.74         0.67 to 48.97   0.11        
  Atrial fibrillation                                                                                                                                                                       
  (−)                   265/607 (43.7)                                            13/607 (2.1)                                                     2.97         0.90 to 9.75    0.07        0.18
  (+)                   15/30 (50.0)                                              3/30 (10.0)                                                      \*           \*              0.99        

\*Odds ratio could not be calculated in the subgroups.CAD indicates coronary artery disease; and RH‐PAT, reactive hyperemia peripheral arterial tonometry.

###### 

Univariate Cox Proportional HR Analysis for the Risk of Ischemic Stroke

                           Univariate                   
  ------------------------ ------------ --------------- ----------
  RH‐PAT index ≤2.0        3.43         1.10 to 10.63   0.03
  Male sex                 0.93         0.34 to 2.56    0.89
  Age, 10‐y increment      2.44         1.54 to 3.99    \<0.0001
  Diabetes mellitus        3.35         1.08 to 10.39   0.04
  Hypertension             4.73         1.35 to 16.60   0.02
  Dyslipidemia             5.4          0.71 to 40.95   0.10
  Smoking history          0.77         0.27 to 2.21    0.62
  Atrial fibrillation      3.93         1.12 to 13.79   0.03
  CHA~2~DS~2~‐VASc score   1.88         1.39 to 2.50    \<0.0001
  Revised FSRS (≥55 y)     1.15         1.03 to 1.24    0.002

FSRS indicates Framingham Stroke Risk Score; HR, hazard ratio; and RH‐PAT, reactive hyperemia peripheral arterial tonometry.

###### 

Multivariate Cox Proportional HR Analysis for the Risk of Ischemic Stroke

                           Multivariate 1   Multivariate 2   Multivariate 3   Multivariate 4                                                                                    
  ------------------------ ---------------- ---------------- ---------------- ---------------- --------------- ------- ------ --------------- ---------- ------ --------------- -------
  RH‐PAT index ≤2.0        3.70             1.18 to 11.59    0.02             3.36             1.05 to 10.78   0.04    3.45   1.11 to 10.72   0.03       5.70   1.40 to 23.29   0.02
  Male sex                 0.77             0.28 to 2.15     0.62                                                                                                               
  Age, 10‐y increment                                                         2.24             1.36 to 3.84    0.001                                                            
  Diabetes mellitus                                                           1.46             0.44 to 4.80    0.53                                                             
  Hypertension                                                                1.96             0.51 to 7.48    0.33                                                             
  Dyslipidemia                                                                2.30             0.29 to 18.27   0.43                                                             
  Smoking history          0.78             0.27 to 2.26     0.65                                                                                                               
  Atrial fibrillation      4.29             1.21 to 15.24    0.02                                                                                                               
  CHA~2~DS~2~‐VASc score                                                                                               1.90   1.40 to 2.56    \<0.0001                          
  Revised FSRS (≥55 y)                                                                                                                                   1.20   1.06 to 1.33    0.001

FSRS indicates Framingham Stroke Risk Score; HR, hazard ratio; and RH‐PAT, reactive hyperemia peripheral arterial tonometry.

Discriminatory Power of RH‐PAT Index for Ischemic Stroke {#jah35062-sec-0018}
--------------------------------------------------------

Risk of ischemic stroke increased with CHA~2~DS~2~‐VASc score (0, 0/101 \[0%\]; 1, 1/263 \[0.4%\]; 2, 5/144 \[3.5%\]; 3, 4/76 \[5.3%\]; 4, 5/36 \[13.9%\]; 5, 1/10 \[10.0%\]; 6, 0/3 \[0%\], 7, 0/1 \[0%\], respectively; *P*\<0.0001) (Figure [2](#jah35062-fig-0002){ref-type="fig"}A). Incidence of ischemic stroke based on CHA~2~DS~2~‐VASc score and RH‐PAT index is shown in Figure [2](#jah35062-fig-0002){ref-type="fig"}B. Finally, we assessed the discriminatory power of RH‐PAT index for ischemic stroke when adding RH‐PAT index to the CHA~2~DS~2~‐VASc score or revised Framingham Stroke Risk Score by calculating net reclassification improvement and integrated discrimination improvement. The discriminatory accuracy for ischemic stroke significantly improved after adding RH‐PAT index to CHA~2~DS~2~‐VASc score (integrated discrimination improvement 0.02, 95% CI, 0.005--0.04, *P*=0.02; net reclassification improvement 0.64, 95% CI, 0.20--1.07, *P*=0.004) and revised Framingham Stroke Risk Score (integrated discrimination improvement 0.03, 95% CI, 0.0001--0.06, *P*=0.049; net reclassification improvement 0.71, 95% CI, 0.23--1.18, *P*=0.003) (Table [5](#jah35062-tbl-0005){ref-type="table"}).

![Incidence of ischemic stroke categorized by CHA~2~DS~2~‐VASc score and reactive hyperemia peripheral arterial tonometry index.\
**A**, Incidence of ischemic stroke according to CHA~2~DS~2~‐VASc score (0, 0/101 \[0%\]; 1, 1/263 \[0.4%\]; 2, 5/144 \[3.5%\]; 3, 4/76 \[5.3%\]; 4, 5/36 \[13.9%\]; 5, 1/10 \[10.0%\]; 6, 0/3 \[0%\], 7, 0/1 \[0%\], respectively; *P*\<0.0001). **B**, Comparison of incidence of ischemic stroke according to CHA2DS2‐VASc score between patients with normal vs abnormal microvascular endothelial dysfunction. RH‐PAT indicates reactive hyperemia peripheral arterial tonometry.](JAH3-9-e015703-g002){#jah35062-fig-0002}

###### 

Reclassification of Ischemic Stroke After Addition of RH‐PAT Index to CHA~2~DS~2~‐VASc Score or Revised Framingham Stroke Risk Score

  Discrimination   CHA~2~DS~2~‐VASc Score         CHA~2~DS~2~‐VASc Score+RH‐PAT Index ≤2.0   Revised FSRS (≥55 y)   Revised FSRS (≥55 y)+RH‐PAT Index ≤2.0
  ---------------- ------------------------------ ------------------------------------------ ---------------------- ----------------------------------------
  C‐statistics     0.82                           0.85                                       0.68                   0.78
  IDI (95% CI)     0.02 (0.005--0.04); *P*=0.02   0.03 (0.0001--0.06); *P*=0.049                                    
  NDI (95% CI)     0.64 (0.20--1.07); *P*=0.004   0.71 (0.23--1.18); *P*=0.003                                      

FSRS indicates Framingham Stroke Risk Score; IDI, integrated discrimination improvement; NDI, net reclassification improvement; and RH‐PAT, reactive hyperemia peripheral arterial tonometry.

Discussion {#jah35062-sec-0019}
==========

In the current study, we show that individuals with PMED had a \>3‐fold increased risk of developing ischemic stroke compared with patients without PMED at baseline, even after adjusting for other cardiovascular risk factors or stroke risk score such as CHA~2~DS~2~‐VASc score and revised Framingham Stroke Risk Score. Patients with PMED had a lower ischemic stroke‐free survival rate compared with individuals with normal microvascular endothelial function at baseline. Moreover, the assessment of PMED added prognostic value to the CHAD~2~DS~2~‐VASc score and revised Framingham Stroke Risk Score (aged ≥55 years) in predicting ischemic stroke. Thus, the current study supports the concept that PMED may predispose to the development of ischemic stroke and/or may act as a surrogate marker of risk for the development of ischemic stroke in the future.

Microvascular Endothelial Dysfunction and the Development of Cerebral Small Vessel Disease {#jah35062-sec-0020}
------------------------------------------------------------------------------------------

Endothelial dysfunction has been linked to an increased risk of cerebral small vessel disease.[26](#jah35062-bib-0026){ref-type="ref"}, [27](#jah35062-bib-0027){ref-type="ref"} One study reported that cerebral vasomotor response to 5‐minute CO~2~‐enriched (5%) gas mixture inhalation, evaluated by the change of blood flow velocity at the right middle cerebral artery at least in part through endothelial function,[28](#jah35062-bib-0028){ref-type="ref"} was associated with symptomatic lacunar infarction, whereas endothelial‐dependent conduit vessel (brachial and carotid artery) reactivity was not.[29](#jah35062-bib-0029){ref-type="ref"} The majority of strokes detected in this study (12/16, 75%) were thought to be related to lacunar infarction caused by small vessel occlusion. Given that RH‐PAT index is an indicator of microvascular endothelial function as opposed to flow‐mediated dilatation of the brachial and carotid artery, which is an indicator of macrovascular endothelial function,[30](#jah35062-bib-0030){ref-type="ref"} the observed association between PMED and ischemic stroke in this study may suggest the critical role of microvascular function on the progression of cerebral small vessel disease. However, the lack of flow‐mediated dilatation data in the majority of the study population limits our ability to meaningfully evaluate the potentially different roles of macro‐ and microvascular endothelial function on the development of cerebral vascular disease.

Incremental Predictive Value of RH‐PAT Index {#jah35062-sec-0021}
--------------------------------------------

In this study population, CHA~2~DS~2~‐VASc score predicted incident ischemic stroke with a C‐statistic of 0.82, though only 4.7% of patients had AF. This finding was consistent with previous observations that showed the prognostic value of CHA~2~DS~2~‐VASc score in predicting ischemic stroke in patients without AF.[13](#jah35062-bib-0013){ref-type="ref"}, [14](#jah35062-bib-0014){ref-type="ref"}, [15](#jah35062-bib-0015){ref-type="ref"}, [16](#jah35062-bib-0016){ref-type="ref"} Interestingly, RH‐PAT index added prognostic value to the CHA~2~DS~2~‐VASc score alone when predicting ischemic stroke with a C‐statistic of 0.85. Also, RH‐PAT index added prognostic value to the revised Framingham Stroke Risk Score in patients ≥55 years. The discriminatory difference was small, but significant (Table [5](#jah35062-tbl-0005){ref-type="table"}). RH‐PAT index seemed to be able to discriminate the risk of ischemic stroke in patients with lower CHA~2~DS~2~‐VASc score (≤2) as well as higher CHA~2~DS~2~‐VASc score (\>2) (Figure [2](#jah35062-fig-0002){ref-type="fig"}B). This observation was not confirmatory, however, and should be validated in different populations.

Limitations {#jah35062-sec-0022}
-----------

This study has several limitations. First, because of its retrospective observational cohort design, it is challenging to derive causal associations from the current study. The evaluation of RH‐PAT index was performed at the discretion of the evaluating physician. Therefore, some selection bias cannot be excluded. Second, despite collecting clinical data from detailed chart review, misclassification and underdetection of incident ischemic stroke may have occurred. Of note, however, as previously mentioned, clinical data were collected by an investigator masked to the RH‐PAT data. Finally, though we calculated the predictive value of the RH‐PAT index using a multivariable analysis, we could not adjust for all the variables because of the small number of events in our sample. Nevertheless, an RH‐PAT index ≤2.0 remained an independent predictor of incident ischemic stroke after adjusting for variables shown to be relevant to ischemic stroke in previous studies.

Conclusions {#jah35062-sec-0023}
===========

PMED, defined by an RH‐PAT index ≤2.0, may predict incident ischemic stroke. These findings underscore the concept of the systemic nature of endothelial dysfunction, which could act as a potential marker to predict future risk of ischemic stroke, though they will require further validation. Whether improvement in PMED translates into a reduced incidence of ischemic stroke remains to be determined. Similarly, the mechanism underlying this association needs to be defined in future studies.
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